Jennifer Lee’s Post

ME Therapeutics is expanding! We're moving into new lab space to support our drug research and development efforts. This move will allow us to explore new drug discovery opportunities and enhance our pipeline. https://lnkd.in/effQ7kG4 #BioTech #HealthcareInnovation #DrugDiscovery #ResearchAndDevelopment #CorporateGrowth #CancerResearch #NewFacilities #Innovation #ScientificResearch

More companies are focusing on developing weight management solutions with GLP-1 drugs. A new player has entered the field with an oral drug that, in preclinical studies, demonstrated a 15% weight reduction over 28 days. Exciting advancements in the realm of weight management solutions using GLP-1 drugs are on the horizon. #WeightManagement #GLP1 #HealthcareInnovation

"(...) Medicine Development and commercialization will be dominated by Data companies with Biotech and Pharma companies playing the role of a substrate supplier to algorithms" (Dr. Michael Zaiac) The writing is on the wall. If this happens, it will be a seismic shift affecting all aspects of healthcare. For many established players, this will pose a major threat to their business model. But within this threat, there is also opportunity. For patients, for Data companies - and for a few Pharma companies who get it right. Thanks Michael Zaiac for spelling it out and Bora Erdemli for posting! #futureofhealthcare #datadrivenmedicine #genAI

We invite you to follow our new LinkedIn page: 'Kerry Solutions for Pharma', designed to keep you connected with the latest innovations and insights in pharma, biotechnology and life sciences. By following our new page, you will: ➡ Be among the first to know about the latest innovative solutions and cutting-edge technologies in the pharma space ➡ Learn about upcoming industry events and webinars that matter to you ➡ Engage with and learn from experts in the field of pharma and biotechnology ➡ Understand how to deliver the best value to help propel your business forward We are excited to have you join us in this new space. #KerryPharma #Pharma #KerryLifeScience

🌟 Meet MOBIO Member Highlight: Array Bridge Inc. 🌟 This month, we're excited to spotlight Array Bridge, a pioneering US-based biotech company making waves in preclinical drug development. For the past six years, Array Bridge has focused on developing a groundbreaking class of drugs through their proprietary Protein Conformational Array (PCA) technology. This cutting-edge approach allows for the screening of compounds that disrupt target protein conformation in ways that traditional allosteric regulators cannot. Here are some key advantages of their PCA technology: 🔍 Broad Selection: Unlike conventional methods that target a single site, PCA can identify molecules that disrupt protein conformation from various sites, expanding the diversity of potential candidates. ⚙️ Multiple Modes of Action: The selected compounds can operate through three distinct mechanisms, not just inhibiting activity. They can block protein interactions, disrupting crucial signal transduction pathways, and even induce degradation of target proteins. 💡 Innovative Discovery Platform: Array Bridge's PCA technology not only enhances drug discovery but also opens new avenues for understanding and targeting complex biological systems. Array Bridge is truly at the forefront of biopharmaceutical innovation, and we’re proud to have them as part of the MOBIO community. Visit our website below to learn more. 👇 https://www.mobio.org/ #MemberHighlight #Biotech #Innovation #DrugDiscovery #ArrayBridge #MOBIO

Last week, our CEO Luigi Aurisicchio attended the 4th Consortium Meeting of the MIRIA EU Project in Prague, hosted by Charles University. Takis, alongside valuable partners from across Europe, holds a central role in this initiative. The MIRIA project aims to develop wide-range antimicrobial nanocoatings for surfaces used in environments such as hospitals, where cross-contamination and contagion risks are significant. At Takis, we are responsible for assessing the antiviral properties of these nanocoatings by evaluating viral infectivity on mammalian cells after prolonged exposure to coated or uncoated materials. Our work aims to determine the nanocoatings' ability to neutralize the virus in laboratory settings, with the goal of selecting the best candidates for pilot-scale production and potential market entry within three years. This meeting provided the opportunity to engage with our European partners and discuss the project developments and milestones achieved so far. Being part of such a diverse and talented consortium is truly enriching, offering us valuable opportunities for learning and growth! #pharma #pharmaceutical #biotech #biotechnology #research #networking #teamwork

🗣️ Meet our facilitator, Firoz Antia 🚀 Get ready to dive deep into the Manufacturing track, at our upcoming Oligonucleotide Therapeutics Xchange 2024, Boston, where we'll tackle the downstream manufacturing challenges for synthetic oligonucleotides: 💥 Chromatography, Desalting, and Isolation 💥 Conjugation 💥 Annealing for Double-Stranded Products 💥 Analytical Characterization 🕰️ Time: 09:05 – 10:05 🗓️ Date: June 21st, 2024 📍 Location: Woburn Hilton Hotel, 2 Forbes Road, Woburn, US 🔑 Reserve your free spot now! https://bit.ly/3wYHLnQ 📢 We're thrilled to have Firoz Antia, Executive Director and Head of Oligonucleotide Development at Biogen, as a facilitator. With over two decades of expertise in drug development, process engineering, and manufacturing, Firoz brings invaluable insights into the latest advancements in oligonucleotide therapeutics. 🎯 Don't miss this opportunity to gain expert knowledge and network with industry leaders! Register now to secure your spot! * Agenda subject to change 💊 Only available for Senior Scientists and above, from Bio and Pharma companies with a drug pipeline. 💊 #OligonucleotideTherapeutics #BiotechEvents #PharmaceuticalManufacturing #BiotechLeadership #OligonucleotideDevelopment #DrugDevelopment #TherapeuticsInnovation #LifeSciences #BostonEvents #Biopharmaceuticals #NetworkingOpportunity #BioPharmaCommunity #hubXchange #Roundtable #FreePass #RegisterNow #ComplimentaryPass

🚀 Last week, the InVivo Biosystems team had the incredible opportunity to attend the Precision Evolution Global Drug Discovery & Preclinical Summit, a game-changing event where our very own Sarah Cheesman, Ph.D., VP of Strategic Partnerships, moderated an expert panel on overcoming bottlenecks to attaining IND approval — a critical topic for revolutionizing the path to new therapies. We were thrilled to find that so many attendees were already aware of the power of zebrafish and 𝘊. 𝘦𝘭𝘦𝘨𝘢𝘯𝘴 as valuable models in preclinical development! 🐟🪱 These models are truly gaining recognition for their potential to accelerate drug discovery and provide earlier insights into therapeutic efficacy and safety. On top of that, we made fantastic new connections and came away energized to continue advancing research with our 𝑹𝒂𝒑𝒊𝒅𝑮𝒆𝒏™ 𝒑𝒍𝒂𝒕𝒇𝒐𝒓𝒎, pushing the frontiers of preclinical testing. Here’s to continuing the momentum and working together to bring innovative solutions to life! 💡 #DrugDiscovery #PreclinicalResearch #Pharma #Biopharma #Zebrafish #Celegans #Biotech #Innovation #InVivoBiosystems #RapidGen #PrecisionEvolutionSummit

#Mitochondria play a vital role in almost all cellular functions and have been recognized as targets for treating a wide range of diseases, of genetic, epigenetic, or exogenous causes. If you want to know about the latest research - this meeting is a must!

As a biotech, adapting your drug development strategies to meet the evolving landscape of nonclinical development can give you a crucial advantage over your competitors. Explore how you can stay ahead of the curve with this webinar: https://okt.to/hPFiSk